Alnylam (Nasdaq: ALNY) has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults ...

New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 ...

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...

A large Finnish project, which is part of the long-term ‘Cardiovascular Risk in Young Finns’ study, found elevated levels of ...

Preclinical candidate data expected in early 2026, with exclusive option for Acumen to develop up to two development candidates for the treatment of Alzheimer’s disease Agreement follows more than one ...

The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

New research shows that signs of Alzheimer’s disease can already be detected in the blood of people as young as their 40s.

A new Yale study has found a promising target for treating the brain fog that can follow COVID-19 and offers new insight into ...

New research reveals Alzheimer’s disease may start in early adulthood, highlighting the need for earlier detection and ...

A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.

A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.

Alzheimer's disease progression linked to microglia fat metabolism, potential new treatment target identified in recent study ...